Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Authors: Ben Tran, Mark Voskoboynik, Sang-We Kim et al.
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Abstract

<jats:p>&lt;p&gt;Supplementary Figure S1. Study design – dose exploration and dose expansion with volrustomig IV Q3W.&lt;/p&gt;</jats:p>

Keywords

dose psupplementary figure study design

Related Articles

Rearrangement of 2-(γ-aminopropyl)benzoxazoles into 2-(α-pyrrolinylamino)phenols: from serendipitous reaction discovery to anti-mycobacterial opportunities

Dylan El Faudel, Gabriel Publicola et al. - Unknown

Read More
Supplementary Figure S6 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy

Toshifumi Ninomiya, Caiyang Fang et al. - Unknown

Read More
Figure 5 from A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer

Alexander Max Funk, Mareike Brieske et al. - Unknown

Read More
Figure 2 from A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer

Alexander Max Funk, Mareike Brieske et al. - Unknown

Read More
Figure S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment

Roberto Moretto, Vittorio Studiale et al. - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0